Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

NewsGuard 100/100 Score

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

"Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche Pharma CEO. "These two products represent our commitment to expanding our product line with a combination of brand and generic drugs, which strengthens our position as a specialty injectables pharmaceutical company."

Duraclon®(clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management. Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction. Please refer to the Bioniche Pharma website for the complete prescribing information, including the boxed warnings, for these products.

Source:

Bioniche Pharma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows antipsychotic drugs increase health risks in dementia patients